Evidence map›Paper›PMID 38716076›Full record

ArticleUpsala journal of medical sciences2024

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.

Lovisa Falkman, Anders Sundin, Britt Skogseid, Johan Botling, Yvette Bernardo, Göran Wallin, Liang Zhang, Staffan Welin, Ieva Lase, Kazhan Mollazadegan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Upsala journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lovisa FalkmanDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Anders SundinDepartment of Radiology, Uppsala University Hospital, Uppsala, Sweden.
Britt SkogseidDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Johan BotlingInstitute of Biomedicine, Department of Laboratory Medicine, Gothenburg University, Gothenburg, Sweden.
Yvette BernardoDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Göran WallinDepartment of Surgery, Örebro University Hospital, Örebro, Sweden.
Liang ZhangDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Staffan WelinDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Ieva LaseDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Kazhan MollazadeganDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Joakim CronaDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metastatic neuroendocrine carcinoma (NEC) is associated with short survival. Other than platinum-based chemotherapy, there is no clear standard regimen. Current guidelines suggest that combination treatment with BRAF-inhibitors should be considered for patients with Methods: This was a single-center retrospective cohort study conducted at Uppsala University Hospital. The included patients 1) had a histopathologically confirmed diagnosis of NEC, 2) were diagnosed between January 1 Results: We screened 48 patients diagnosed with NEC between January 1 Conclusions:

Indexed as

Carcinoma, NeuroendocrineOximesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonesAdultAgedFemaleHigh-Throughput Nucleotide SequencingHumansImidazolesMaleMiddle AgedMutationRetrospective StudiesBRAF protein, humandabrafenibImidazolesOximesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibBRAF-inhibitorsBRAF-mutationNeuroendocrine carcinomaneuroendocrine neoplasmsmall-molecule targeted drugtargeted therapy

Identifiers

PMID38716076
PMCPMC11075439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.